药物与手术治疗的原发性醛固酮增多症患者心房颤动发生率与盐皮质激素受体活性
结果显示,MR拮抗剂治疗后肾素仍被抑制的PA患者房颤风险显著高于原发性高血压患者(校正HR 2.55,95%CI 1.75-3.71),而肾素明显升高或手术治疗者与原发性高血压患者无显著差异。
要点
- MR拮抗剂治疗后肾素仍抑制的PA患者房颤风险显著高于原发性高血压患者。
- 肾素明显升高或肾上腺切除术治疗的PA患者房颤风险与原发性高血压患者无显著差异。
- 充分MR阻断或去除醛固酮来源可能与降低房颤发生风险相关。
核心结论
- MR拮抗剂治疗后肾素仍被抑制(提示MR阻断不足)的PA患者,房颤发生风险显著高于原发性高血压患者。
- MR拮抗剂治疗使肾素明显升高(提示MR阻断充分)或肾上腺切除术治疗的患者,房颤风险与原发性高血压患者无显著差异。
研究设计与样本
- 队列研究,纳入年龄≥18岁的PA患者和年龄匹配的原发性高血压患者,排除有房颤、心肌梗死、充血性心力衰竭或卒中病史者。
- 数据收集于1991年至2016年底,来自一家学术医疗中心,平均随访约8年。
主要发现
- MR拮抗剂治疗后肾素仍抑制的PA患者与原发性高血压患者相比,校正HR为2.55(95%CI 1.75-3.71)。
- 上述患者10年累积房颤发生率校正差异为每100人多余14.1例(95%CI 6.7-21.5)。
- MR拮抗剂治疗后肾素明显升高者及肾上腺切除术者与原发性高血压患者相比,房颤风险无统计学显著差异。
- 研究入组时及随访期间各组血压相似。
关键数值与推荐
- 肾素抑制定义为血浆肾素活性< 1 ng/mL/h,肾素明显升高定义为≥ 1 ng/mL/h。
临床怎么用
- 对接受MR拮抗剂治疗的PA患者,可监测肾素水平以评估MR阻断是否充分。
- 肾素仍被抑制者可能提示MR阻断不足,需考虑调整治疗以降低房颤风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Primary aldosteronism (PA) is an ideal condition to evaluate the role of the mineralocorticoid receptor (MR) in the pathogenesis of atrial fibrillation (AF). OBJECTIVE: To investigate whether MR antagonist therapy or surgical adrenalectomy in PA influence the risk for incident AF. DESIGN: This cohort study included patients aged 18 years and older. Patients with PA and age-matched patients with essential hypertension were identified via electronic health records. Patients with a history of AF, myocardial infarction, congestive heart failure, or stroke were excluded. Data were collected between 1991 and the end of 2016 in an academic medical center, with a mean follow-up duration of approximately 8 years. EXPOSURES: Patients with PA treated with MR antagonists or surgical adrenalectomy were compared with patients with essential hypertension. Patients with PA who were treated with MR antagonists were categorized by whether their plasma renin activity remained suppressed (< 1 ng/mL/h) or substantially increased (≥ 1 ng/mL/h), as proxies for insufficient or sufficient MR blockade. MAIN OUTCOMES AND MEASURE: Incident AF. RESULTS: A total of 195 patients with PA who were treated with MR antagonists and 201 patients with PA treated with surgical adrenalectomy were included, as well as 40 092 age-matched patients with essential hypertension. Despite similar blood pressure at study entry and throughout follow-up, patients with PA who were treated with MR antagonists whose renin remained suppressed had a higher risk for incident AF than patients with essential hypertension (adjusted HR, 2.55 [95% CI, 1.75-3.71]). They also had an adjusted 10-year cumulative AF incidence difference of 14.1 (95% CI, 6.7-21.5) excess cases per 100 persons compared with patients with essential hypertension. In contrast, patients with PA who were treated with MR antagonists and whose renin increased and patients with PA who were treated with surgical adrenalectomy had no statistically significant difference in risk for incident AF compared with patients with essential hypertension. CONCLUSIONS AND RELEVANCE: When compared with patients with essential hypertension, patients with PA treated with MR antagonists such that renin remained suppressed (as a proxy for insufficient MR blockade) had a significantly higher risk for incident AF; however, treatment of PA with MR antagonists to substantially increase renin (suggesting sufficient MR blockade), or with surgical adrenalectomy (to remove the source of aldosteronism), was associated with no significant difference in risk for developing AF. These findings add to the growing body of evidence suggesting that MR blockade may be a potential therapy to decrease the incidence of AF.
引用
- Hundemer GL, Curhan GC, Yozamp N, et al. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. JAMA Cardiol. 2018. PMID: 30027227. doi:10.1001/jamacardio.2018.2003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。